Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...

Only one out of 24 patients with hepatitis had an elevated INR (1.49), and it was probably attributable to a more severe clinical course with bacterial superinfection of skin lesions and suspected ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

In Rwanda, cancer remains a leading health challenge, with breast, cervical, and prostate cancers being among the most prevalent. According to Dr. Theoneste Maniragaba, the Director of the Cancer ...

Patient A demonstrated substantial lesion shrinkage and decreased Apparent Diffusion Coefficient ... (Top) Patient A cortical and subcortical changes. (Bottom) Patient B cortical and subcortical ...

Transmission is also possible from contact with patient saliva, lesion exudate, or contaminated dressings (Centers for Disease Control and Prevention [CDC], 2001). Symptoms begin 12 to 14 days ...

Although true bifurcation lesions are associated with a high risk of procedural complications, the differential prognostic implications of percutaneous coronary intervention for true bifurcations ...